Outlook Therapeutics (OTLK) Common Equity (2015 - 2026)

Outlook Therapeutics (OTLK) has 12 years of Common Equity data on file, last reported at -$29.0 million in Q1 2026.

• Common Equity for Q1 2026 came in at -$29.0 million, up 10.68% year-over-year; the trailing twelve-month figure through Mar 2026 was -$29.0 million (up 10.68% YoY), and the FY2025 annual result was -$32.2 million, up 55.95% from the prior year.
• Common Equity improved to -$29.0 million in Q1 2026 per OTLK's latest filing, from -$38.5 million in the prior quarter.
• Over five years, Common Equity peaked at $36.0 million in Q1 2022 and troughed at -$134.2 million in Q1 2024.
• A 5-year average of -$27.3 million and a median of -$29.0 million in 2026 frame the typical range for Common Equity.
• The sharpest annual moves came in 2022 and 2024: Common Equity surged 89.62% in 2022, then sank 1420.55% in 2024.
• A 5-year view of Common Equity shows it stood at $15.8 million in 2022, then tumbled by 254.48% to -$24.3 million in 2023, then slumped by 106.59% to -$50.3 million in 2024, then increased by 23.35% to -$38.5 million in 2025, then gained by 24.79% to -$29.0 million in 2026.
• Business Quant data shows OTLK's Common Equity at -$29.0 million in Q1 2026, -$38.5 million in Q4 2025, and -$32.2 million in Q3 2025.